Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|April 1, 2014

BioPharm International

  • BioPharm International-04-01-2014
  • Volume 27
  • Issue 4

Line of Environmental Measurement Products

Line of Environmental Measurement Products

Cole-Parmer offers the Digi Sense line of test and measurement products, from environmental testing meters to performance monitoring equipment. Several items are precalibrated to save time and cost.

The Digi-Sense brand currently includes 25 models of thermometers, infrared devices, humidity meters, anemometers, light meters, and manometers. Digi-Sense also features a line of temperature probes with customization available for various applications.

Cole-Parmer

Articles in this issue

over 12 years ago

UPLC Separation Intergrates into Mass Spectrometers

over 12 years ago

Control Strategies for Synthetic Therapeutic Peptide APIs Part II: Raw Material Considerations

over 12 years ago

FDA and Manufacturers Seek a More Secure Drug Supply Chain

over 12 years ago

High-Performance Separation-Electrospray Ionization System

over 12 years ago

Biotech IPOs on a Hot Streak

over 12 years ago

Global Instability Affects the Pharma Market in Brazil

over 12 years ago

Raw Material Variability

over 12 years ago

Monoclonal Antibodies Key to Unlocking the Biosimilars Market

over 12 years ago

Publishing Beyond the Printed Page

over 12 years ago

Biopharma Outsourcing Activities Update

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more